Status of marine biological prospecting Marjo Vierros, UNU-IAS - PowerPoint PPT Presentation

1 / 15
About This Presentation
Title:

Status of marine biological prospecting Marjo Vierros, UNU-IAS

Description:

... Deep seabed genetic resources Information difficult to find due to its commercially sensitive nature Several biotechnology ... applications, biotechnology, ... – PowerPoint PPT presentation

Number of Views:240
Avg rating:3.0/5.0
Slides: 16
Provided by: c3166
Category:

less

Transcript and Presenter's Notes

Title: Status of marine biological prospecting Marjo Vierros, UNU-IAS


1
Status of marine biological prospectingMarjo
Vierros, UNU-IAS
2
The need for improved information on marine
biological prospecting
  • There is a lack of detailed information about
    marine genetic resources, including in areas
    beyond national jurisdiction, to inform the
    policy debate.
  • This includes information about
  • What types of genetic resources are being
    collected and where?
  • Does the collection lead to commercial
    applications?
  • What types of products are being
    developed/marketed and by whom?
  • What are their potential/actual values?
  • What types of benefit sharing agreements have
    been developed?

3
Developing the tools
  • UNU-IAS has developed web-based resource tools
    that provide information about bioprospecting
    activities in
  • Antarctica (funded by Belgian Federal Ministry
    of Environment and UNEP, proposal welcomed at XXX
    ATCM in 2007, and product to be presented at XXXI
    ATCM in 2008 )
  • Pacific Island countries (in collaboration with
    SPREP and others, recognized need by member
    states of SPREP. Presented at the 8th Pacific
    Islands Conference on Nature Conservation and
    Protected Areas in October 2007)
  • Marine areas (in collaboration with UNESCO)
  • Arctic (UNU-IAS)
  • The resource tools include searchable databases

4
http//www.bioprospector.org/bioprospector/
5
(No Transcript)
6
(No Transcript)
7
Deep seabed genetic resources
  • Information difficult to find due to its
    commercially sensitive nature
  • Several biotechnology and other companies
    involved in patenting of deep sea genetic
    resources, product development and collaboration
    with research institutions
  • Most of the interest has focused on deep sea
    microbes (extremophiles), mainly from
    hydrothermal vents, but also sediments, methane
    seeps and other deep sea environments
  • Development of novel enzymes for industrial and
    chemical processes
  • DNA polymerases, pharmaceutical and cosmetics
    applications
  • Several patents exist and a number of enzymes
    from hydrothermal vent bacteria are now on the
    market - include samples sourced from the
    Midocean Ridge
  • Difficult to tell whether samples collected from
    areas beyond national jurisdiction

8
Some examples of commercial developments
  • Fuelzyme enzyme was developed on the basis of
    samples collected from a deep-sea hydrothermal
    vent, likely from the Mid-Atlantic Ridge. This
    enzyme, which is currently marketed by Verenium
    (USA), is used in ethanol production from corn
  • Vent polymerase is a thermostable enzyme sourced
    form a hydrothermal vent archaebacteria in Italy.
    It is marketed by New England Biolabs (USA) for
    use in DNA cloning, sequencing and amplification.
  • Venuceane is an enzyme showing antioxidant
    properties, based on a bacteria collected from
    Guyamas Basin in the Gulf of California. It is
    marketed for use in cosmetics by Sederma (France)
  • The enzyme market is expected to grow 7.6 per
    year to 6 billion in 2011

9
Other marine organisms used for commercial
purposes
  • Marine sponges
  • have shown promise for treatment of cancer,
    asthma, alzheimers, arthritis, inflammation, etc.
  • Several are in clinical trials
  • At least one potential cancer drug from deep sea
    sponge (Gulf of Mexico)
  • Sponge reefs beyond national jurisdiction may be
    of interest to bioprospecting
  • Corals (particularly soft corals), molluscs (sea
    slugs, sea hares, cone snails), tunicates, worms
    (including hydrothermal vent tubeworms),
    bryozoans, vertebrates (fish, sharks)

10
Some examples
  • Pain medication Prialt, based on a synthetic
    derivative from marine cone shell venom from
    Indonesia, marketed by Elan Corporation (Revenue
    from sales 12.1 million in 2006)
  • Yondelis, an anti-cancer agent originally
    sourced from a Caribbean sea slug, has received
    Authorization for Commercialization from the
    European Commission for advanced soft tissue
    sarcoma. It is marketed by the Spanish company
    PharmaMar.
  • Anti-freeze proteins from cold ocean fish are
    being marketed for uses ranging from improving
    the survival of biological materials, for example
    in transplant surgery to lengthening the shelf
    life of frozen foods, such as ice cream.
  • The Antarctic marine algae Durvillea antarctica
    is one of the ingredients in Extra Firming Day
    Cream produced by the French Company Clarins.

11
Antarctica
  • The majority (56) of the records in the
    Antarctic Biological Prospecting database
    originate from the marine environment of the
    Southern Ocean
  • They cover a number of actual or proposed uses,
    including in the food and beverage industry, as
    pharmaceuticals, in industrial applications,
    biotechnology, cosmetics and personal care
    products, chemical processing, aquaculture and
    agriculture and environmental remediation
  • Most (60) of these are based on various products
    derived from krill, while the rest consist mainly
    of products derived from sponges, bacteria, fish
    and algae.

12
Patents filed on Antarctic marine organisms
  • Over 500 patents filed for krill
  • Krill pink gold

13
Environmental impacts
  • In general, initial sampling consists of
    relatively small quantities (ex. an individual
    sponge or other organism)
  • Repeated collection of promising organisms may
    cause environmental impact, as the quantities
    required may be larger. Sensitive and pristine
    habitats and rare species, and species with
    limited distribution may be particularly at risk
  • Laboratory techniques to produce synthetics and
    derivatives may lessen environmental impact, and
    also produce economic benefits to companies
    (repeated sampling is costly) - however not
    always done (ex. Krill)
  • Scale of bioprospecting activity is not always
    known, and information about the population and
    life history parameters of the source organism
    are not always available.
  • Precautionary approach important

14
Benefit-sharing
  • Information about benefit-sharing difficult to
    find
  • The developers of Bengamides, compounds extracted
    from a marine sponge in Fiji with potential
    cancer-fighting potential, have committed 2-5 of
    the proceeds from sales to support further
    research in Fiji.

15
Thank you!
Write a Comment
User Comments (0)
About PowerShow.com